Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...
Woman's World on MSN

Blood in your urine? 5 bladder cancer symptoms you should never ignore

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...
Morningstar

Francis Medical Receives FDA 510(k) Clearance for Use of the Vanquish® Water Vapor System for Prostate Tissue Ablation in Patients with Intermediate Risk Prostate Cancer

MINNEAPOLIS, Dec. 2, 2025 /PRNewswire/ -- Francis Medical, Inc., a privately-held medical device company developing the breakthrough Vanquish® Water Vapor Ablation System for the management of ...
Nasdaq

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026

PRINCETON, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and ...
Business Insider

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle ...

PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty ...
Cure Today

What to Know About Early-Stage Urothelial Carcinoma

Urothelial carcinoma is the most common bladder cancer, with stage 1 indicating early-stage disease confined to the bladder lining. Diagnosis involves urinalysis, cystoscopy, TURBT, and imaging to ...
Hosted on MSN

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call Transcript

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call Transcript August 9, 2025 Operator: Good day, and thank you for standing by. Welcome to the UroGen Pharma Second Quarter 2025 Earnings Call.
Seeking Alpha

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade ...

24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) PRINCETON, N.J., Aug. 05, 2025 (GLOBE ...
KTLA

Deion Sanders’ cancer battle, and the telltale symptom you shouldn’t ignore

News that NFL legend Deion Sanders is recovering after a battle with bladder cancer has sparked an important conversation about a form of cancer that is often under-discussed and underfunded in ...
MedPage Today

New Treatment Options for Non-Muscle-Invasive Bladder Cancer

or on the link below. Non–muscle-invasive bladder cancer (NMIBC) comprises 75% of newly diagnosed bladder cancer and poses significant clinical challenges because of high recurrence and progression ...
Seeking Alpha

U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive ...

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today ...